Effect of Dysfunctional Urate Transporter on Kidney Function Characterized
The ABCG2 transporter drives urate excretion in the kidney and intestine.
The ABCG2 transporter drives urate excretion in the kidney and intestine.
Investigators explored the causality between the liability of gout on hypertension and the liability of hypertension on gout.
Early identification of patients at high risk of hyperuricemia using the triglyceride-glucose index may permit prompt intervention.
Gout patients are susceptible to breakthrough COVID-19 infection and severe outcomes despite vaccination.
In addition to cardiovascular disease, gout is associated with an increased risk of dying from genitourinary conditions, such as chronic kidney disease.
Investigators report findings from the MIRROR RCT trial, which compared pegloticase plus methotrexate vs placebo for uncontrolled gout.
The novel cocrystal of febuxostat and telmisartan was evaluated for the treatment of comorbid hyperuricemia/gout and hypertension.
Researchers used data from the ACR RISE registry to evaluate a treat-to-target approach among patients with gout receiving urate-lowering therapy.
Based on recent study findings, Robert Keenan, MD, discusses the risk for cardiovascular events among patients with gout.
Clinicians currently decide whether or not to prescribe urate-lowering therapies in patients with asymptomatic hyperuricemia.